Biotech | October 22, 2021
WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections
Second interchangeable biosimilar product approved by agency
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Subscribe To Our Newsletter & Stay Updated
